Bar-Or A - Search Results

1

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. Freedman MS, et al. Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5. Neurology. 2011. PMID: 21975206 Clinical Trial.

2

Biology of adult human microglia in culture: comparisons with peripheral blood monocytes and astrocytes.

Williams K, Bar-Or A, Ulvestad E, Olivier A, Antel JP, Yong VW. Williams K, et al. J Neuropathol Exp Neurol. 1992 Sep;51(5):538-49. doi: 10.1097/00005072-199209000-00009. J Neuropathol Exp Neurol. 1992. PMID: 1517774

3

Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Kim HJ, et al. Clin Immunol. 2002 Aug;104(2):105-14. doi: 10.1006/clim.2002.5258. Clin Immunol. 2002. PMID: 12165271 Clinical Trial.

4

Do myelin-directed antibodies predict multiple sclerosis?

Antel JP, Bar-Or A. Antel JP, et al. N Engl J Med. 2003 Jul 10;349(2):107-9. doi: 10.1056/NEJMp030098. N Engl J Med. 2003. PMID: 12853581 No abstract available.

5

Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.

Kim HJ, Biernacki K, Prat A, Antel JP, Bar-Or A. Kim HJ, et al. Clin Immunol. 2004 Apr;111(1):38-46. doi: 10.1016/j.clim.2004.01.004. Clin Immunol. 2004. PMID: 15093550

6

Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.

Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Giuliani F, et al. J Neuroimmunol. 2005 Jan;158(1-2):213-21. doi: 10.1016/j.jneuroim.2004.09.006. J Neuroimmunol. 2005. PMID: 15589056

7

Microglia and multiple sclerosis.

Jack C, Ruffini F, Bar-Or A, Antel JP. Jack C, et al. J Neurosci Res. 2005 Aug 1;81(3):363-73. doi: 10.1002/jnr.20482. J Neurosci Res. 2005. PMID: 15948188 Review.

8

Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.

Duszczyszyn DA, Beck JD, Antel J, Bar-Or A, Lapierre Y, Gadag V, Haegert DG. Duszczyszyn DA, et al. Clin Exp Immunol. 2006 Feb;143(2):305-13. doi: 10.1111/j.1365-2249.2005.02990.x. Clin Exp Immunol. 2006. PMID: 16412055 Free PMC article.

9

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. O'Connor PW, et al. Neurology. 2006 Mar 28;66(6):894-900. doi: 10.1212/01.wnl.0000203121.04509.31. Neurology. 2006. PMID: 16567708 Clinical Trial.

10

Natalizumab effects on immune cell responses in multiple sclerosis.

Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A. Niino M, et al. Ann Neurol. 2006 May;59(5):748-54. doi: 10.1002/ana.20859. Ann Neurol. 2006. PMID: 16634035 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

413 results

Search Page

Filters